In response to @melburnian’s post above.
“Given that IV and IP injection demonstrate efficacy in metastatic models with both CF33-CD19t plus CAR T cells and other tumor models with other CF33 derivatives, we think that the barrier to metastatic treatment is surmountable, based on our current data.”
This sounds fairly promising to me.
metastatic = Solid tumours (Huge market)
surmountable = Able to be overcome.
CF33/CD19/CAR T = IMU’s weapon of choice.
GLTAH. Watch this space IMO. Onward IMU
Thanks for posting @melburnian
Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-176
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
-0.004(7.55%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.3¢ | 4.9¢ | $1.061M | 21.17M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 6583733 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 1287081 | 5 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |